Scarica l'app Stockscreener
1.13
3.42%
-0.04
Dopo l'orario di chiusura:
1.15
0.02
+1.77%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CHRS Giù?
Forum
Previsione
Coherus Oncology Inc Borsa (CHRS) Ultime notizie
Eligible shareholders may share proceeds from Coherus' assets tied to similar medicines. The sale process has begun. - stocktitan.net
Coherus Oncology Shares Down on Plans to Sell Biosimilar Assets - Moomoo
Coherus initiates sale of legacy biosimilars assets - Investing.com
Coherus Oncology Starts Process to Sell Remaining Biosimilar Assets - marketscreener.com
Coherus initiates sale of legacy biosimilars assets By Investing.com - Investing.com Nigeria
Coherus (CHRS) Stock: Slides -0.82%, Support at $1.15 2026-09-17Moving Average Ribbon - careplusvn.com
Coherus at Morgan Stanley healthcare conference: oncology push gains traction - Investing.com Canada
CHRS: Strong commercial growth and promising oncology pipeline drive optimism for future milestones - TradingView
CHRS: Strong commercial execution and promising oncology pipeline position the company for growth - TradingView
Transcript : Coherus Oncology, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-16-2026 12 - marketscreener.com
CHRS: Innovative oncology focus drives pipeline progress, with key data readouts expected by year-end - TradingView
CHRS: Strategic oncology focus drives revenue growth and key clinical milestones, with major data readouts ahead - TradingView
CHRS: Pipeline advances and strong LOQTORZI sales position for growth, with major data readouts ahead - TradingView
Coherus Oncology at 2026 Global Healthcare Conference: pipeline, sales push - Investing.com Canada
Coherus BioSciences stock reacts to BlackRock stake and latest oncology focus - ad-hoc-news.de
CHRS Q2 2026 Earnings: Narrower-than-Expected Loss Drives 2.59% Share GainPost-Earnings Reaction - vinanet.vn
Coherus to Participate in Upcoming Investor Conferences - Yahoo Finance
Coherus Oncology files $50M at-the-market sales agreement with Leerink Partners - TradingView
Coherus (CHRS) Quarter in Focus: The Bottom-Line Figure Beats Its Comparison at the Close; Closing Reaction: Shares Finish 4.23% Down for the Current SessionEarnings Growth Analysis - vinanet.vn
Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug Development - Seeking Alpha
Coherus (CHRS) Q2 2026 Results: Reported EPS Tops Expectations in Latest Trading; Market Reaction: Shares Finish 16.52% UpEarnings Power Value - vinanet.vn
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com - Investing.com India
CHRS Looks 10.6% Overvalued on GF Value™ - GuruFocus
Coherus Oncology Secures $55M Term Loan, Extends Debt Maturity to 2031 - Minichart
Coherus Declares Special Dividend of Biosimilar Contingent Value Rights, Payable Oct. 7 to Holders of Record Sept. 30 - marketscreener.com
Coherus Oncology Announces Special Dividend Of Biosimilar Contingent Value Rights - tradingview.com
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights - GlobeNewswire
Coherus will give eligible holders rights to cash from former assets—but they may expire unpaid - Stock Titan
Coherus Oncology, Inc., Coherus Intermediate Corp, Surface Oncology, LLC, and InteKrin Therapeutics Inc., Enter into Loan and Security Agreement - marketscreener.com
Q3 EPS Estimates for Coherus Oncology Cut by HC Wainwright - MarketBeat
Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript - The Globe and Mail
ETFs Investing in Coherus Oncology, Inc. Stocks - TradingView
CHRS Maintained by Guggenheim -- Price Target Lowered to $10.00 - GuruFocus
Coherus Oncology Is Maintained at Buy by Guggenheim - Moomoo
Earnings call transcript: Coherus Oncology posts Q2 2026 EPS beat, shares fall - Investing.com Nigeria
H.C. Wainwright Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Coherus Oncology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Coherus Oncology Reports Second Quarter 2026 Financial Results and Provides Business Update - The Manila Times
Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: - GuruFocus
Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: LOQTORZI Growth and Pipeline ... - finance.yahoo.com
Coherus Oncology, Inc. 2026 Q2 10-Q Highlights: Financials, Risks, and Forward-Looking Statements for Investors - Minichart
Coherus Oncology Q2 2026 Results: LOQTORZI Revenue Growth, Pipeline Progress, and Financial Update - Minichart
CHRS Looks 83.5% Overvalued on GF Value™ - GuruFocus
Coherus Oncology Q2 Earnings Call Highlights - MarketBeat
Coherus Oncology : Reports Second Quarter 2026 Financial Results and Provides Business Update - marketscreener.com
Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results - MarketBeat
CHRS: LOQTORZI sales rose 15% in Q2, with key clinical data readouts expected later in 2026 - TradingView
Coherus Oncology Inc reports results for the quarter ended June 30Earnings Summary - tradingview.com
Is Coherus Oncology Inc (CHRS) Worth the Investment After Q2 Ear - GuruFocus
Coherus Oncology (CHRS) Reports Q2 Loss, Misses Revenue Estimates - Yahoo Finance
Coherus Oncology (NASDAQ: CHRS) posts Q2 2026 loss amid growing LOQTORZI revenue - Stock Titan
Coherus Oncology: Q2 Earnings Snapshot - Barchart.com
Coherus Oncology Q2 revenue rises 40% on higher LOQTORZI volume, but slightly falls below estimates - TradingView
Coherus Oncology Q2 Revenue Rises To $14.3 Million - quiverquant.com
CHRS: Q2 2026 revenue up 39% year-over-year, net loss narrows, and pipeline advances continue - TradingView
BRIEF-Coherus Oncology Q2 Net Income USD -20.631 Million - TradingView
Coherus projects October data disclosure as cancer trials mature - Stock Titan
3.06%
2.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):